- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
PET/CT boosts classification of incidental adrenal masses
In what is possibly the largest study of its kind, Harvard University researchers have shown that PET/CT can reliably tell whether unsuspected adrenal lesions discovered while managing oncologic patients are benign or malignant.
In what is possibly the largest study of its kind, Harvard University researchers have shown that PET/CT can reliably tell whether unsuspected adrenal lesions discovered while managing oncologic patients are benign or malignant.
Incidental adrenal lesions in patients with cancer require accurate characterization because their status can significantly affect staging, therapy, and prognosis. Several imaging tests are available to offer a helping hand, including contrast/noncontrast CT and MRI. None, however, has proven conclusive.
A 2006 Massachusetts General Hospital study of 38 patients found PET/CT to be sensitive and specific for the characterization of incidental adrenal lesions (Blake MA, Slattery JM, Kalra MK. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy-initial experience. Radiology 2006;238(3):970-977). The results encouraged an investigative group led by Dr. Giles W. L. Boland, an associate professor of radiology at Mass General, to validate the findings in a larger cohort of patients.
Between October 2004 and March 2007, Boland and colleagues evaluated 150 patients with various malignancies, including lymphoma and lung, head and neck, and colorectal cancer. All patients underwent noncontrast PET/CT and a follow-up CT scan six months later. The researchers confirmed that PET/CT was highly effective for differentiating benign from malignant adrenal disease in this patient population. Based on a qualitative analysis, PET/CT yielded sensitivity, specificity, accuracy, and positive and negative predictive values for characterization of benign adrenal "incidentalomas" of 100%, 97%, 98%, 87%, and 100%, respectively.
Boland cautioned the study had several limitations, including the retrospective nature of the sample. He called for careful consideration of many other criteria, including the Hounsfield unit and standardized uptake value measurements, adrenal wash-outs, and lesion size assessments. But the findings showed a way forward, he said.
"PET/CT is indeed an accurate test," Boland said.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
